DYN, Trendline bounce on the 1hr chart coming up. Long on a bounce at $26, short on trendline break. Possibly 20% either side. Multiple PT upgrades last week and only 15% float is retail hence the big % daily moves.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.35 USD
−317.42 M USD
0.00 USD
87.33 M
About Dyne Therapeutics, Inc.
Sector
Industry
CEO
John G. Cox
Website
Headquarters
Waltham
Founded
2017
FIGI
BBG00NSGPJD0
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
DYN - Falling WedgeOn the chart, we can se a falling wedge occurring.
The stock has held its strong support for a long period of time, and we are now expecting it to go to the upside after bullish consolidation.
MACD seems to make either a consolidating or bullish crossing.
Our first target is based on the forming,
Successful Inverted H&S Pattern Displaying the features of a inverted H&S pattern
The best chance of catching a bull run is on the right arm
$DYN is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Dyne Therapeutics is a pre-clinical stage developer of treatment candidates for various serious muscle diseases.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and ot
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of DYN is 7.73 USD — it has increased by 6.11% in the past 24 hours. Watch Dyne Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Dyne Therapeutics, Inc. stocks are traded under the ticker DYN.
DYN stock has fallen by −6.39% compared to the previous week, the month change is a −37.91% fall, over the last year Dyne Therapeutics, Inc. has showed a −70.43% decrease.
We've gathered analysts' opinions on Dyne Therapeutics, Inc. future price: according to them, DYN price has a max estimate of 66.00 USD and a min estimate of 17.00 USD. Watch DYN chart and read a more detailed Dyne Therapeutics, Inc. stock forecast: see what analysts think of Dyne Therapeutics, Inc. and suggest that you do with its stocks.
DYN stock is 5.51% volatile and has beta coefficient of 1.81. Track Dyne Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Dyne Therapeutics, Inc. there?
Today Dyne Therapeutics, Inc. has the market capitalization of 845.01 M, it has decreased by −18.85% over the last week.
Yes, you can track Dyne Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Dyne Therapeutics, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
DYN earnings for the last quarter are −0.88 USD per share, whereas the estimation was −0.94 USD resulting in a 6.03% surprise. The estimated earnings for the next quarter are −0.85 USD per share. See more details about Dyne Therapeutics, Inc. earnings.
Dyne Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
DYN net income for the last quarter is −89.54 M USD, while the quarter before that showed −97.13 M USD of net income which accounts for 7.81% change. Track more Dyne Therapeutics, Inc. financial stats to get the full picture.
No, DYN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 191 employees. See our rating of the largest employees — is Dyne Therapeutics, Inc. on this list?
Like other stocks, DYN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Dyne Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Dyne Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Dyne Therapeutics, Inc. stock shows the sell signal. See more of Dyne Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.